- Discovery of novel inhibitors of human phosphoglycerate dehydrogenase by activity-directed combinatorial chemical synthesis strategy
-
Serine, the source of the one-carbon units essential for de novo purine and deoxythymidine synthesis plays a crucial role in the growth of cancer cells. Phosphoglycerate dehydrogenase (PHGDH) which catalyzes the first, rate-limiting step in de novo serine biosynthesis has become a promising target for the cancer treatment. Here we identified H-G6 as a potential PHGDH inhibitor from the screening of an in-house small molecule library based on the enzymatic assay. We adopted activity-directed combinatorial chemical synthesis strategy to optimize this hit compound. Compound b36 was found to be the noncompetitive and the most promising one with IC50 values of 5.96 ± 0.61 μM against PHGDH. Compound b36 inhibited the proliferation of human breast cancer and ovarian cancer cells, reduced intracellular serine synthesis, damaged DNA synthesis, and induced cell cycle arrest. Collectively, our results suggest that b36 is a novel PHGDH inhibitor, which could be a promising modulator to reprogram the serine synthesis pathway and might be a potential anticancer lead worth further exploration.
- Gou, Kun,Luo, Youfu,Luo, Yuan,Sun, Qingxiang,Tan, Yuping,Tao, Lei,Zhao, Yinglan,Zhou, Xia,Zhou, Yue,Zuo, Zeping
-
-
- XPA INHIBITOR COMPOUNDS AND THEIR USE
-
The present disclosure relates to certain compounds having binding affinity for XPA, and uses thereof. Specifically, the present disclosure relates to the use of XPA inhibitors as described herein in in methods of treating cancer.
- -
-
Page/Page column 46-47
(2019/04/16)
-
- Efficient Synthesis of Five Types of Heterocyclic Compounds via Intramolecular Elimination Using Ultrasound-Static Heating Technique
-
An experimental technique, ultrasound-static heating, has been developed for the efficient synthesis of heterocyclic compounds. The technique involves ultrasonic irradiation and static heating processes. First, the ultrasonic irradiation process is performed to form an intermediate of the heterocyclic compound under mild conditions and the subsequent static heating process (heating the intermediate under solvent-free conditions without stirring) produces the target heterocyclic compounds via intramolecular elimination.
- Jiang, Hongfei,Dong, Xueyang,Jin, Xin,Zhu, Danyang,Yin, Ruijuan,Yu, Rilei,Wan, Shengbiao,Zhang, Lijuan,Jiang, Tao
-
p. 2009 - 2013
(2018/07/31)
-
- Design and Structure-Guided Development of Novel Inhibitors of the Xeroderma Pigmentosum Group A (XPA) Protein-DNA Interaction
-
XPA is a unique and essential protein required for the nucleotide excision DNA repair pathway and represents a therapeutic target in oncology. Herein, we are the first to develop novel inhibitors of the XPA-DNA interaction through structure-guided drug design efforts. Ester derivatives of the compounds 1 (X80), 22, and 24 displayed excellent inhibitory activity (IC50 of 0.82 ± 0.18 μM and 1.3 ± 0.22 μM, respectively) but poor solubility. We have synthesized novel amide derivatives that retain potency and have much improved solubility. Furthermore, compound 1 analogs exhibited good specificity for XPA over RPA (replication protein A), another DNA-binding protein that participates in the nucleotide excision repair (NER) pathway. Importantly, there were no significant interactions observed by the X80 class of compounds directly with DNA. Molecular docking studies revealed a mechanistic model for the interaction, and these studies could serve as the basis for continued analysis of structure-activity relationships and drug development efforts of this novel target.
- Gavande, Navnath S.,Vandervere-Carozza, Pamela,Mishra, Akaash K.,Vernon, Tyler L.,Pawelczak, Katherine S.,Turchi, John J.
-
p. 8055 - 8070
(2017/10/18)
-
- KU INHIBITORS AND THEIR USE
-
The present disclosure relates to certain compounds having binding affinity for Ku, and uses thereof. Specifically, the present disclosure relates to the use of Ku inhibitors as described herein in site-specific genome engineering technologies, including but not limited to CRISPR/Cas9, Zinc finger nuclease (ZFN), Transcription activator-like effector nuclease (TALEN), and meganuclease. The present disclosure also relates to kits useful for site-specific genome engineering that include at least one compound as described herein.
- -
-
Page/Page column 38; 39
(2017/12/29)
-
- Viable and straightforward approach to the preparation of water soluble pyrazol-5-one derivatives through glycoconjugation
-
The synthesis of water soluble pyrazol-5-one azo-dyes has been achieved. 6′-Aminolactosetriacetonide 9 was selected as the key building block to glyconjugate the pyrazole ring at its 3 position via a carboxamide or via a benzeneamide moiety in position 1 of the heterocycle. Diethyl-3-oxopentandionate 2 led eventually to a bicyclic compound, hampering the glyconjugation coupling process. The values of the molar extinction coefficients (ε) confirmed the tendency of pyrazolone azo dyes to exist in their tautomeric hydrazo form (especially in polar solvents); whereas the presence of substituents on the phenylazo group influenced the visible absorption maxima negligibly.
- Bianchini, Roberto,Bonanni, Marco,Corsi, Massimo,Infantino, Angela Simona
-
p. 8636 - 8644
(2012/10/29)
-
- Synthesis, crystal structure and evaluation of cancer inhibitory activity of 4-[indol-3-yl-methylene]-1H-pyrazol-5(4H)-one derivatives
-
A series of 4-(1H-indol-3-yl-methylene)-1H-pyrazol-5(4H)-one derivatives have been synthesised. The Z structure of 4-[(1-methyl-1H-indol-3-yl)methylene]- 3-phenyl-1-p-tolyl-1H-pyrazol-5-one was determined by X-ray crystallography. The antitumour activity was evaluated against five cancer cells by MTT assay. [(1H-Indol-3-yl)methylene]-1-(2,4-dinitrophenyl)- 3-methyl-1H-pyrazole-5-one and 4-{4-[(1-benzyl-1H-indol-3-yl)methylene]-3-methyl-5-oxo-4,5-dihydro-1Hpyrazol- 1-yl}-benzoic acid have similar anticancer activity with 5-UF on the test cancer cells (exception of A375). Almost all the target compounds displayed antitumour activity against A549 and PC-9, and those with benzyl at 1- position of indole had higher activity against PC-9 (IC50 value lower than 30 μM). Those with benzyl at the indole and carboxyl at the phenyl part of of pyrazole were more active against PC-9 and A549 cells, providing a good indication for subsequent optimisation as lung cancer inhibitory agents.
- Jing, Lingling,Wang, Liang,Zhao, Yinglan,Tan, Rui,Xing, Xiumei,Liu, Ting,Huang, Wencai,Luo, Youfu,Li, Zicheng
-
p. 691 - 696
(2013/02/23)
-
- Virtual ligand screening of the p300/CBP histone acetyltransferase: Identification of a selective small molecule inhibitor
-
The histone acetyltransferase (HAT) p300/CBP is a transcriptional coactivator implicated in many gene regulatory pathways and protein acetylation events. Although p300 inhibitors have been reported, a potent, selective, and readily available active-sitedirected small molecule inhibitor is not yet known. Here we use a structure-based, in silico screening approach to identify a commercially available pyrazolone- containing small molecule p300 HAT inhibitor, C646. C646 is a competitive p300 inhibitor with a Ki of 400 nM and is selective versus other acetyltransferases. Studies on site-directed p300 HAT mutants and synthetic modifications of C646 confirm the importance of predicted interactions in conferring potency. Inhibition of histone acetylation and cell growth by C646 in cells validate its utility as a pharmacologic probe and suggest that p300/CBP HAT is a worthy anticancer target.
- Bowers, Erin M.,Yan, Gai,Mukherjee, Chandrani,Orry, Andrew,Wang, Ling,Holbert, Marc A.,Crump, Nicholas T.,Hazzalin, Catherine A.,Liszczak, Glen,Yuan, Hua,Larocca, Cecilia,Saldanha, S. Adrian,Abagyan, Ruben,Sun, Yan,Meyers, David J.,Marmorstein, Ronen,Mahadevan, Louis C.,Alani, Rhoda M.,Cole, Philip A.
-
p. 471 - 482
(2011/08/06)
-
- Methods and Compositions for Modulating P300/CBP Activity
-
The present invention relates to a method for identifying compounds that modulate the activity of p300/CBP. Compounds of the invention are identified by designing or screening for a compound which binds to at least one amino acid residue of the newly identified lysine-CoA inhibitor binding site, L1 loop, electronegative pocket, or electronegative groove of the HAT domain of p300/CBP and testing the compound for its ability to modulate the activity of p300/CBP. Compositions and methods for preventing or treating diseases or disorders associated with p300/CBP are also provided as is a method for producing a semi-synthetic HAT domain.
- -
-
Page/Page column 19
(2010/09/05)
-
- OXIDATIVE COLOR-DEVELOPING COMPOUNDS, SALTS THEREOF, PROCESS FOR PRODUCTION OF THE SAME, REAGENT COMPOSITIONS AND TEST TOOLS MADE BY USING THE SAME
-
It is an object of the present invention to provide a means for measuring a concentration of various components rapidly with high accuracy and high sensitivity. The present invention is to provide an oxidative chromogenic compound or salt thereof represented by the following chemical formula (1): wherein R1 and R2 are each independently a linear or branched alkyl group having 1 to 5 carbon atoms; R3, R4, R5, R6 and R7 are each independently a hydrogen atom, a carboxyl group or a sulfonic acid group, or salt thereof, provided that at least one of R3 to R7 is a carboxyl group or a sulfonic acid group, or salt thereof, and the others are hydrogen atoms, and the production method thereof, and the reagent composition and test instrument using the same.
- -
-
Page/Page column 13
(2010/01/07)
-
- Discovery of new Gram-negative antivirulence drugs: Structure and properties of novel E. coli WaaC inhibitors
-
Heptosyltransferases such as WaaC represent promising and attractive targets for the discovery of new Gram-negative antibacterial drugs based on antivirulence mechanisms. We report herein our approach to the identification of the first micromolar inhibitors of WaaC and the preliminary SAR generated from this family of 2-aryl-5-methyl-4-(5-aryl-furan-2-yl-methylene)-2,4-dihydro-pyrazol-3-on es identified by virtual screening.
- Moreau,Desroy,Genevard,Vongsouthi,Gerusz,Le Fralliec,Oliveira,Floquet,Denis,Escaich,Wolf,Busemann,Aschenbrenner
-
scheme or table
p. 4022 - 4026
(2009/04/06)
-
- Pyrazolone methylamino piperidine derivatives as novel CCR3 antagonists
-
The discovery and optimization of a novel class of potent CCR3 antagonists is described. Details of synthesis and SAR are given together with some ADME properties of selected compounds. An optimal balance between activities, physicochemical properties, and in vitro metabolic stability was reached by the proper choice of substituents.
- Pegurier, Cecile,Collart, Philippe,Danhaive, Pierre,Defays, Sabine,Gillard, Michel,Gilson, Frederic,Kogej, Thierry,Pasau, Patrick,Van Houtvin, Nathalie,Van Thuyne, Marc,van Keulen, BerendJan
-
p. 4228 - 4231
(2008/02/09)
-
- Thrombopoietin mimetics
-
Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.
- -
-
-
- DRUGS COMPRISING COMBINATION OF ANTITHROMBOTIC AGENT WITH PYRAZOLONE DERIVATIVE
-
It is intended to provide drugs for treating and/or preventing ischemic diseases which are safe and have little side effects. Namely, drugs comprising a combination of an antithrombotic agent and a pyrazolone derivative defined in the description or its pharmaceutically acceptable salt.
- -
-
-
- Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
-
A method for treating neoplasia involving the administration of certain pyrazolinone derivatives.
- -
-
-
